TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12404190
Drug: Sequential combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combined hormone‐replacement therapy (HRT) - conjugated equine estrogen 0.625 mg/d for 28 days and 5 mg of medroxyprogesterone acetate during the last 14 days
Study: 10023944
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (300 mg once daily for 12 weeks)
Study: 7775624
Drug: Local intraarterial
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local intraarterial infusion of 25 micrograms/h somatostatin
Study: 7775624
Drug: Systemic control
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic control infusion
Study: 1651741
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy followed by prophylactic cranial irradiation (PCI) for disease-free patients
Study: 6130666
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of beta-receptor blockers
Study: 6130666
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of beta-receptor blockers
Study: 27552592
Drug: Omega-3 supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplements (1,470mg DHA and 147mg EPA daily for 12 weeks)
Study: 24393602
Drug: Secukinumab Monthly
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab Monthly regimen (Weeks 0, 4, 8)
Study: 18004129
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 mg/d for 1 week then 200 mg/d for 6 weeks)
Study: 12468952
Drug: Metoclopramide injection
Normalized name: metoclopramide Injection
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide injection (n = 8)
Study: 380868
Drug: naproxen, 500
Normalized name: Naproxen, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen, 500 mg/day for 1 week
Study: 380868
Drug: diclofenac, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac, 100 mg/day for 1 week
Study: 31101782
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 15 mg/kg/day for 12 months
Study: 31101782
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 800 mg/day plus Vitamin C 500 mg/day for 12 months
Study: 23410808
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg monthly intravitreal injection)
Study: 23410808
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (quarterly intravenous verteporfin coupled with PDT)
Study: 9492128
Drug: Buffered lidocaine
Normalized name: buffered lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered lidocaine (first injection)
Study: 9492128
Drug: Buffered lidocaine
Normalized name: buffered lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered lidocaine (second injection)
Study: 3139830
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg) after 30-day therapy
Study: 31768589
Drug: Daily TPTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily TPTD (20-μg injection daily for 6 months)
Study: 31768589
Drug: Weekly TPTD
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly TPTD (56.5-μg injection 1×/week for 6 months)
Study: 1771090
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg amitriptyline
Study: 18433307
Drug: MRK adenovirus
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRK adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine (3-dose regimen, doses ranging from 3 x 10^6 to 1 x 10^11 viral particles per 1-mL dose)
Study: 17294878
Drug: Conventional hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hospital treatment
Study: 11938802
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal treatment added during prednisone reduction
Study: 11938802
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment (control group)
Study: 9104548
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg once daily for 12 weeks
Study: 8478303
Drug: Dirithromycin 500
Normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dirithromycin 500 mg/day orally once daily for 10-14 days
Study: 8478303
Drug: Erythromycin 1000
Normalized name: erythromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 1000 mg/day orally four times daily for 10-14 days
Study: 30051366
Drug: Surgical interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical interventions for rectal cancer
Study: 23837549
Drug: Constant Current
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant Current (CC) stimulation
Study: 20581391
Drug: Sirolimus (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (target dose, 2 mg daily)
Study: 18766092
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of feedback and debriefing
Study: 10848884
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance tests (ITT) performed during menstrual cycle phases in women
Study: 10848884
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance tests (ITT) performed in men
Study: 2581075
Drug: Timolol 30
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol 30 mg
Study: 2581075
Drug: Timolol 60
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol 60 mg
Study: 15207544
Drug: 5% sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sodium lauryl sulphate (SLS) solution
Study: 15207544
Drug: Aqueous Cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous Cream BP
Study: 26133711
Drug: 1 µg/kg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg/kg of DEX
Study: 16618363
Drug: Prebiotic formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic formula (0.6 g GOS/FOS/100 ml)
Study: 16618363
Drug: Probiotic formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic formula (6.0 x 10^9 cfu Bifidobacterium animalis/100 ml)
Study: 14744166
Drug: Venlafaxine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 300 mg/day
Study: 14744166
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to alternate SRI (either paroxetine or venlafaxine) after 4-week tapering phase
Study: 8276300
Drug: Intraperitoneal radioactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal radioactive therapy followed by thio-TEPA
Study: 8276300
Drug: 32P treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 32P treatment
Study: 16354890
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives
Study: 31083170
Drug: Community-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based intervention program (6 sessions, once weekly)
Study: 23625331
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (500 mg, 2 capsules per day for 6 weeks)
Study: 23625331
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules per day for 6 weeks)
Study: 22212765
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n=33) received weekly topic-based reading instructions and five telephone consultations with an audiologist.
Study: 16418085
Drug: Rapid-sequence intubation
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-sequence intubation (RSI) with etomidate (0.3 mg/kg) and succinylcholine (1.5 mg/kg)
Study: 16418085
Drug: Etomidate-only intubation
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate-only intubation (EOI) with etomidate (0.3 mg/kg)
Study: 9001838
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/benazepril 20 mg
Study: 11090788
Drug: Low-dose calcium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose calcium antagonists
Study: 24353344
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (vitamin E, 400 IU; vitamin C, 500 mg; selenium, 50 μg)
Study: 30919899
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg daily
Study: 16208784
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml bupivacaine 0.25% into the margin
Study: 16208784
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml bupivacaine 0.25% into the cavity
Study: 16208784
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml physiological saline into the cavity
Study: 2837105
Drug: Ethanol (0.42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.42 g/kg) + marihuana (2.4% THC)
Study: 2837105
Drug: Ethanol (0.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.85 g/kg) + marihuana (2.4% THC)
Study: 2837105
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ethanol (0.42 g/kg) + placebo marihuana
Study: 2837105
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ethanol (0.85 g/kg) + placebo marihuana
Study: 2837105
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ethanol (0.42 g/kg) + marihuana (2.4% THC)
Study: 2837105
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ethanol (0.85 g/kg) + marihuana (2.4% THC)
Study: 2837105
Drug: Ethanol (0.42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.42 g/kg) + marihuana (0.0004% THC)
Study: 2837105
Drug: Ethanol (0.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.85 g/kg) + marihuana (0.0004% THC)
Study: 21680702
Drug: SRT501 (micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT501 (micronized resveratrol) 5.0 g daily for 14 days
Study: 14555261
Drug: Clodronate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (100 mg im/week) plus calcium (1000 mg) and vitamin D (800 UI)
Study: 14555261
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg) and vitamin D (800 UI) alone
Study: 8741720
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy targeted specifically on the single symptom of their delusional belief(s)
Study: 1565419
Drug: RGP daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: RGP daily wear (DWRGP)
Study: 31685212
Drug: Gemcabene 300
Normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcabene 300 mg for 4 weeks
Study: 31685212
Drug: Gemcabene 600
Normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcabene 600 mg for 4 weeks
Study: 31685212
Drug: Gemcabene 900
Normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcabene 900 mg for 4 weeks
Study: 29767677
Drug: docetaxel +
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel + bavituximab 3 mg/kg
Study: 23625982
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg prednisolone
Study: 7557813
Drug: Amitriptyline 30
Normalized name: amitriptyline 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 30 mg/d
Study: 7557813
Drug: Flupentixol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol 1.5 mg/d
Study: 7557813
Drug: Clotiazepam 15
Normalized name: clotiazepam
DrugBank: Clotiazepam (DB01559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotiazepam 15 mg/d
Study: 7557813
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs compared
Study: 7235102
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (personal contact added to standard treatment)
Study: 24908596
Drug: 2% Uncaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Uncaria tomentosa gel
Study: 11451620
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen and progesterone (Estraderm TTS 50 and 0.4 mg progesterone vaginal suppository) (n=7)
Study: 11451620
Drug: Oral oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestrogen and progesterone (2 mg Progynova and 0.4 mg progesterone vaginal suppository) (n=8)
Study: 8066557
Drug: Inhaled acetaldehyde
Normalized name: acetaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled acetaldehyde (0.8 mg/ml for 4 minutes)
Study: 8066557
Drug: Inhaled acetaldehyde
Normalized name: acetaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled acetaldehyde with terfenadine
Study: 8066557
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo and inhaled saline
Study: 2848786
Drug: levamisole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: levamisole (2.5 mg/kg twice weekly for 2 years or until tumor progression)
Study: 28539066
Drug: Water-based treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based treatment
Study: 28539066
Drug: Land-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land-based treatment
Study: 26062180
Drug: Electroacupuncture applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electroacupuncture applied to bilateral Fushe (SP 13) and Shuidao (ST 28); 2 Hz/50 Hz, retaining for 30 min, one treatment
Study: 24183981
Drug: delNS1‐trivalent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: delNS1‐trivalent vaccine at 7.0log10 TCID50/subject
Study: 12379622
Drug: Anti-TNF monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-TNF monoclonal antibody infliximab
Study: 2651489
Drug: Alprazolam, 0.5-6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam, 0.5-6.0 mg/day
Study: 2651489
Drug: Adinazolam mesylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam mesylate, 10-120 mg/day
Study: 21116
Drug: Fluphenazine/nortriptyline (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine/nortriptyline (specific antidepressant together with an anxiolytic)
Study: 21116
Drug: Potassium clorazepate
Normalized name: potassium clorazepate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium clorazepate (pure anxiolytic)
Study: 28244612
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea tablets
Study: 24970794
Drug: Uninterrupted oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninterrupted oral anticoagulation (UAC)
Study: 21941091
Drug: ZOSTAVAX (refrigerator-stable
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZOSTAVAX (refrigerator-stable formulation), single dose administered within 6 months of expiry
Study: 21932952
Drug: Subcutaneous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous unfractionated heparin
Study: 16520474
Drug: Chloroquine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (150 mg/d for 12 months)
Study: 15486520
Drug: Milnacipran 75
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran 75 mg daily
Study: 15486520
Drug: Milnacipran 150
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran 150 mg daily
Study: 7799026
Drug: Ciprofloxacin (CIP)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CIP) 750 mg orally twice per day
Study: 7799026
Drug: Trimethoprim/sulfamethoxazole (TMS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (TMS) 160 mg trimethoprim and 800 mg sulfamethoxazole orally twice per day
Study: 87620
Drug: Apomorphine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine combined with domeperidone (peripheral dopamine receptor blocker)
Study: 17252567
Drug: PDT (Photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT (Photodynamic Therapy) with MAL (16% methyl aminolevulinate)
Study: 11843370
Drug: Amnioinfusion (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amnioinfusion (500 mL of normal saline over 30 minutes)
Study: 9863486
Drug: Erythromycin 40
Normalized name: erythromycin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 40 mg after placebo
Study: 9863486
Drug: Erythromycin 40
Normalized name: erythromycin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 40 mg after atropine
Study: 9863486
Drug: Erythromycin 40
Normalized name: erythromycin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 40 mg after sumatriptan
Study: 9863486
Drug: Erythromycin 200
Normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 200 mg after atropine
Study: 9863486
Drug: Erythromycin 200
Normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 200 mg after sumatriptan
Study: 2229750
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy in patients with proximal left anterior descending coronary artery stenosis ≥ 70% and ejection fraction < 0.50
Study: 2229750
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy in patients with three vessel coronary artery disease and ejection fraction < 0.50
Study: 31538453
Drug: Chlo‐SITE (chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlo‐SITE (chlorhexidine based local drug delivery) applied in 1 pocket in 2 quadrants after full mouth disinfection
Study: 31538453
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment in 2° and 3° quadrants)
Study: 27902641
Drug: Neostigmine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (50 μg/kg)
Study: 27902641
Drug: Neostigmine followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine followed by Sugammadex (50 μg/kg neostigmine, then 2 mg/kg sugammadex after 3 min)
Study: 19615696
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta (IFNbeta) treatment
Study: 17302058
Drug: Wendan Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wendan Tablet (WT)
Study: 12765886
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg kg(‐1))
Study: 11104345
Drug: Supratentorial radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supratentorial radiation dose of 25 Gy
Study: 11104345
Drug: Supratentorial radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supratentorial radiation dose of 35 Gy
Study: 1651860
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg on day 1, plus 250 mg/day on days 2-5)
Study: 1651860
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (625 mg every eight hours for ten days)
Study: 7042074
Drug: Peptichemio (75-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptichemio (75-100 mg/m2 IV q 3-4 weeks)
Study: 7042074
Drug: L-PAM (30-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PAM (30-40 mg/m2 IV q 3-4 weeks)
Study: 3898925
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol
Study: 31658494
Drug: Intravenous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous tobramycin
Study: 28882926
Drug: ProAsk intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ProAsk intervention delivered on a tablet device
Study: 24975366
Drug: Risperidone (single-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (single-dose, two-period crossover study)
Study: 27092789
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg once a day for 12 weeks
Study: 21501328
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER 4 mg once a day for 12 weeks
Study: 19709754
Drug: Escitalopram, 10
Normalized name: Escitalopram, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, 10 mg
Study: 19709754
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of escitalopram and bupropion